

August 28, 2018



# Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company's business on Thursday, September 6 at 10:50am ET.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link ([www.rodmanevents.com](http://www.rodmanevents.com)) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, [www.auriniapharma.com](http://www.auriniapharma.com). A replay will also be archived on the site following the event.

## ***About Aurinia***

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing *voclosporin*, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at [www.auriniapharma.com](http://www.auriniapharma.com).

## ***We seek safe harbor.***

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20180828005266/en/>

**Aurinia Pharmaceuticals Inc.**  
**Investor Contact:**

Celia Economides  
VP, Corporate & Public Affairs  
[IR@auriniapharma.com](mailto:IR@auriniapharma.com)

or

**Media:**

Christopher Hippolyte, 212-364-0458  
[Christopher.hippolyte@inventivhealth.com](mailto:Christopher.hippolyte@inventivhealth.com)

Source: Aurinia Pharmaceuticals Inc.